| Revenue growth | FY26 Enterprise Revenue ₹196.91 Cr vs FY25 ₹168.75 Cr (calculated). |
|---|---|
| Margins | Clinics ARPU ₹10-13k; Disease Reversal ₹50-60k per patient. |
| Demand visibility | Strong, footfall increased to 8.58 Lakh in FY26. |
| Management confidence | High, targeting 5 crore patients and 1,000 clinics by 2030. |
Growth
FY26 enterprise revenue reached ₹196.91 Cr; clinic revenue at ₹166.55 Cr (Services 61.95%, Products 38.05%).
Outlook
Targeting 1,000 clinics and 10 hospitals by 2028/2030. Scaling to 250-300 beds in 12-15 months.
Risks
High dependence on Maharashtra (247/320 clinics). Significant reliance on franchise network (~77% revenue share).
Earnings Call filed with NSE, NSE: MADHAVBAUG. Summary written with AI assistance from the document.
Vaidya Sane Ayurved Laboratories Ltd: key numbers
- Share price
- ₹161.25
- Market cap
- ₹169.5 Cr
- Revenue (annual)
- ₹106.9 Cr
- Net profit (annual)
- ₹8.99 Cr
- P/E (TTM)
- 18.9×Sector 37.2×
- Promoter holding
- 66.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaidya Sane Ayurved Laboratories Ltd
All →Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
Vaidya Sane Ayurved Laboratories Board Meeting Outcome
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories Earnings Call: Key Takeaways
Madhavbaug reported FY26 revenue of ₹106.91cr (+18.89% YoY) and PAT of ₹8.99cr. The company is pivoting from wellness to higher-value disease reversal programs and expanding hospital capacity.